Full Press Release Details
IceCure's ProSense at the European
Society of Breast Imaging
Congress 2025: Unlocking De-Escalation of Care in Breast Cancer,
Positive Results from 5 Independent Studies
exclusive workshop was filled to capacity - Unlocking De-Escalation of Care:
Cryoablation for Breast Cancer led by Key Opinion
Leaders Dr. Federica Di Naro
Dr. Luc a Gra a-Lopez
5 abstracts presented from doctors using
ProSense for breast cancer cryoablation in Europe
Dr. Francesca Pugliese awarded Young Physician-Scientist
Grant for her study on
post-procedure lesion conspicuity imaging as potential noninvasive biomarker for
treatment evaluation; selected
as one of the top 5 abstracts
Israel, September 30, 2025 - IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the
"Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical
tumor removal, today announced its participation at the European Society of Breast Imaging ("EUSOBI")
Congress 2025 in Aberdeen, United Kingdom, on September 25-27, 2025.
"ProSense represents the next step in the de-escalation
of care for early-stage breast cancer," said Eyal Shamir, IceCure's Chief Executive Officer. "Prior advances in screening,
early detection, and adjuvant therapies have shifted treatment from radical surgery to breast-conserving, personalized approaches. With
the breast cancer indication already approved in the European Union, ProSense offers a minimally invasive, outpatient procedure with
superior cosmetic outcomes and effectiveness comparable to surgery. Interest in this shift is clear- our workshop at EUSOBI was
filled to capacity, and there was strong reception to the five independent investigator studies, highlighting the growing momentum for
ProSense adoption in the treatment of early-stage breast cancer in Europe
ProSense was featured in the following:
The ProSense Cryoablation System provides a minimally invasive
treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal
zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.
ProSense enhances patient and provider value by accelerating recovery,
reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense opens
that door to fast and convenient office-based procedures for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets
advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical
tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense system is marketed and sold
worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.
Forward Looking Statements
press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions or variations of such words
are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press
release when it discusses the belief that ProSense represents the next step in the de-escalation of care for early-stage breast
cancer and that ProSense offers superior cosmetic outcomes and effectiveness comparable to surgery. Historical results of scientific
research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical
or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially
from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital
expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its
products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its
relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents
and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic
and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors
section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27,
2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company
undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Information available on or through the websites mentioned in this press release does not form part of this press release.